Enzon names Dr. Ivan Horak Chief Scientifc Officer
Advertisement
Enzon Pharmaceuticals, Inc. announced the appointment of Ivan Horak, M.D. to the position of Executive Vice President of Research and Development and Chief Scientific Officer. In his new position Dr. Horak will oversee all aspects of Enzon's research and development, regulatory affairs, and quality assurance activities.
Dr. Horak brings an impressive background in drug development to Enzon and is a board certified medical oncologist. He has held a number of senior medical and scientific positions in the pharmaceutical industry, as well as the National Cancer Institute (NCI).
Dr. Horak joins Enzon from Immunomedics, Inc., where he served as Chief Scientific Officer since July 2003 and Executive Vice President of Research and Development since May 2002. Before joining Immunomedics, Dr. Horak was employed by Pharmacia as a Vice President for Clinical Oncology, where he helped direct the global development of oncology compounds from 1999 to 2002, including Camptosar® for metastatic colorectal cancer.
From 1996 to 1999, Dr. Horak held a variety of clinical research positions at Janssen Research Foundation, a subsidiary of the Johnson & Johnson Company, including International Director for Clinical Research and Development, Oncology.
Prior to joining Janssen, Dr. Horak spent nine years at the NCI where he most recently served as a cancer expert for the Metabolism Branch.
In addition to over 50 scientific publications, Dr. Horak is a member of several prominent medical societies and has served on various committees for the American Association for Cancer Research and the International Union Against Cancer. He also serves on the editorial board of the prestigious journal, Cancer Research.
Most read news
Topics
Organizations
Other news from the department people

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Eastman Opens New Specialty Fluids Testing Lab in Singapore

Detecting fluorescence signals from nanoscale thin films - New possibilities in product labeling
Laying down a discerning membrane

A silk coat for diamonds
Hydrogen fuel for thought - Rice researchers find metallacarboranes may meet DOE storage goals

New theory explains superconductivity in spun graphene trilayers - The study, carried out by CSIC scientists, lays the foundations for understanding the mechanisms of certain unconventional superconducting materials
AkzoNobel to expand colloidal silica capacity in Sweden
Bayer CropScience signs Agreement with GVK Biosciences on early-stage research projects
Methanex and BP to proceed with the Construction of the Methanol Facility
Contract for propylene oxide plant based on Evonik-Uhde process for Chinese Province of Jilin

New 2D alloy combines five metals, breaks down CO2 - It's first demonstrated use of a 2D, multi-metallic alloy
